Extract

•To evaluate the efficacy of MK-5172A as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA < LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy •To evaluate the safety and tolerability of MK-5172A in the immediate treatment group relative to the placebo treatment of the deferred treatment group.

Inclusion criteria

• Hepatitis C

Links

• euctr
• euctr
• euctr